Skip to content

To Investigate the Safety & Tolerability of HDCD-092330 in Healthy Volunteers

A Randomized, Double Blind, Placebo Controlled, Multiple Cohort, Sequential Dose Escalation Phase 1 Clinical Study to Evaluate the Safety & Tolerability of HDCD-092330 in Healthy Volunteers - NIL

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/04/065687
Enrollment
40
Registered
2024-04-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy adult male or female subjects aged between 18- 45 years. 2.Healthy subjects as determined by the investigator based on a medical evaluation including medical history, physical examination, laboratory tests (as specified in Appendix1). 3.Subjects who refrain from taking any oral/ topical medication at least 15 days prior and during the study period. (Paracetamol to be allowed within 15 days prior to study, non-regular SOS medications to be allowed during the study) 4.Subjects who have not participated in any other similar clinical study within the last 3 months of screening. 5.Subjects willing to sign informed consent and follow the study procedure

Exclusion criteria

Exclusion criteria: 1.Subjects with known clinically significant cardiovascular, respiratory, cerebrovascular, hepatic, congenital or any other disorder that can interfere with the study conduct and outcome in the opinion of the Investigator. (Subject with any chronic medical condition under control to be also excluded). 2.Subjects with known history of GIT disorders like GERD, Gastritis or any other discomfort (as assessed by GSRS score (Appendix 2) more than 1 for any one of the 15 questions to be excluded) 3.Subjects with history of significant renal disease or urinary symptoms; past history of urinary stones, or history of any previous urogenital invasive procedures. 4.Subjects with known history or present condition of allergic response to the study drug or any ingredients in the investigational product. 5.Pre-existing systemic diseases (auto immune disorders, hormonal replacement, etc.) necessitating long-term medications. 6.Pregnant and lactating women (as assessed by UPT & History of Amenorrhea). 7.Male subjects who refrain to use adequate contraception and not donate sperm from first admission to the study until 90 days after the follow-up visit. 8.Known alcohol or any other substance abuse according to DSM-V criteria. 9.Any other reason (physical, psychological or social) that can interfere with the subject’s compliance to the study in the opinion of the Investigator.

Design outcomes

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Primary

MeasureTime frame
Safety and efficacy Assessment of GI (Gastrointestinal) tolerability through GSRS (Gastrointestinal Symptom Rating Scale). Timepoint: Day 1 & Day 7

Countries

India

Contacts

Public ContactDr Soorya Narayan H

Himalaya Wellness Company

dr.anindya@himalayawellness.com8067549920

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026